Christian Junghanß

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

Dietrich W. Beelen, Rudolf Trenschel, Matthias Stelljes et al. · The Lancet Haematology · 2019 · 147 citations · Full text

Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma

Agnieszka Korfel, Eckhard Thiel, Peter Martus et al. · Neurology · 2015 · 116 citations · Full text

ABVD in Older Patients With Early-Stage Hodgkin Lymphoma Treated Within the German Hodgkin Study Group HD10 and HD11 Trials

Boris Böll, Helen Görgen, Michael Fuchs et al. · Journal of Clinical Oncology · 2013 · 109 citations · Full text

Prognostic Role of Circulating Tumor Cells during Induction Chemotherapy Followed by Curative Surgery Combined with Postoperative Radiotherapy in Patients with Locally Advanced Oral and Oropharyngeal Squamous Cell Cancer

Johanna Inhestern, Katrin Oertel, Viola Stemmann et al. · PLoS ONE · 2015 · 69 citations · Full text